A Study of the ReCor Medical Paradise System in Clinical Hypertension

NAActive, not recruitingINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2020

Study Completion Date

May 31, 2025

Conditions
HypertensionVascular Diseases
Interventions
DEVICE

The Paradise® Renal Denervation Ultrasound System

Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.

DEVICE

Sham Procedure

Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.

Trial Locations (49)

1200

Cliniques Universitaires St Luc, Brussels

10010

New York University School of Medicine, New York

10032

Columbia University / NewYork Presbyterian Hospital, New York

19104

University of Pennsylvania, Philadelphia

23560

Sana Kliniken Lübeck GmbH, Lübeck

29403

Medical University of South Carolina, Charleston

30308

Emory University Hospital Midtown, Atlanta

31300

Clinique Pasteur, Toulouse

32605

The Cardiac and Vascular Institute, Gainesville

33000

Hôpital Saint-André - CHU Bordeaux, Bordeaux

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University, Nashville

40225

University Clinic Dusseldorf, Düsseldorf

44106

University Hospitals Cleveland Medical Center, Cleveland

44195

Cleveland Clinic, Cleveland

46237

Franciscan Health Indianapolis, Indianapolis

55131

Katholisches Klinikum Mainz, Mainz

55407

Minneapolis Heart Institute, Minneapolis

59000

CHRU Lille - Institut Coeur Poumon, Lille

62794

Southern Illinois University Medicine, Springfield

66421

University Clinic of Saarland, Homburg

69004

Hôpital de la Croix Rousse, Lyon

70121

Ochsner Heart and Vascular Insitute, New Orleans

75015

Hôpital Européen Georges-Pompidou, Paris

75093

The Heart Hospital Baylor Plano, Plano

84112

University of Utah, Salt Lake City

89502

Renown Institute for Heart& Vascular Health, Reno

90211

Cedars-Sinai Medical Center, Los Angeles

91054

University Clinic Erlangen, Erlangen

95816

Sutter Health Medical Center, Sacramento

06904

Stamford Hospital, Stamford

02114

Massachusetts General Hospital, Boston

02120

The Brigham and Women's Hospital, Boston

08015

Deborah Heart and Lung Center, Browns Mills

27599-7075

University of North Carolina at Chapel Hill School of Medicine, Chapel Hill

D-91054

Universitäts-Herzzentrum Freiburg-Bad Krozingen GmbH, Freiburg im Breisgau

04289

Leipzig Heart Center, Leipzig

6229 HX

Maastricht University Hospital, Maastricht

3015 CE

Erasmus Medical Center, Rotterdam

3584 CX

University Medical Center Utrecht, Utrecht

80-952

Medical University of Gdansk, Gdansk

04-628

Institute of Cardiology, Warsaw

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

SW7 2AZ

Imperial College London, Hammersmith Hospital, London

Unknown

The Essex Cardiothoracic Centre - Basildon & Thurrock University Hospitals, Basildon

EX2 5DW

Royal Devon and Exeter Hospital (Wonford), Exeter

TN37 7RD

Conquest Hospital - Hastings, Hastings

EC1A 7BE

St Bartholomew's Hospital, London

NG5 1PB

Nottingham University Hospitals NHS Trust, Nottingham

All Listed Sponsors
lead

ReCor Medical, Inc.

INDUSTRY

NCT02649426 - A Study of the ReCor Medical Paradise System in Clinical Hypertension | Biotech Hunter | Biotech Hunter